These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9732415)

  • 1. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
    Ibeanu GC; Goldstein JA; Meyer U; Benhamou S; Bouchardy C; Dayer P; Ghanayem BI; Blaisdell J
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1490-5. PubMed ID: 9732415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.
    Ibeanu GC; Blaisdell J; Ghanayem BI; Beyeler C; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Daly AK; Goldstein JA
    Pharmacogenetics; 1998 Apr; 8(2):129-35. PubMed ID: 10022751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
    Ferguson RJ; De Morais SM; Benhamou S; Bouchardy C; Blaisdell J; Ibeanu G; Wilkinson GR; Sarich TC; Wright JM; Dayer P; Goldstein JA
    J Pharmacol Exp Ther; 1998 Jan; 284(1):356-61. PubMed ID: 9435198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
    Brøsen K; de Morais SM; Meyer UA; Goldstein JA
    Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.
    Ibeanu GC; Blaisdell J; Ferguson RJ; Ghanayem BI; Brosen K; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Goldstein JA
    J Pharmacol Exp Ther; 1999 Aug; 290(2):635-40. PubMed ID: 10411572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
    De Morais SM; Wilkinson GR; Blaisdell J; Meyer UA; Nakamura K; Goldstein JA
    Mol Pharmacol; 1994 Oct; 46(4):594-8. PubMed ID: 7969038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
    Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
    Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
    Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
    de Morais SM; Wilkinson GR; Blaisdell J; Nakamura K; Meyer UA; Goldstein JA
    J Biol Chem; 1994 Jun; 269(22):15419-22. PubMed ID: 8195181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and functional characterization of new potentially defective alleles of human CYP2C19.
    Blaisdell J; Mohrenweiser H; Jackson J; Ferguson S; Coulter S; Chanas B; Xi T; Ghanayem B; Goldstein JA
    Pharmacogenetics; 2002 Dec; 12(9):703-11. PubMed ID: 12464799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world.
    Xie HG; Stein CM; Kim RB; Wilkinson GR; Flockhart DA; Wood AJ
    Pharmacogenetics; 1999 Oct; 9(5):539-49. PubMed ID: 10591534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
    Bertilsson L
    Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
    Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
    Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population.
    Xie HG
    Life Sci; 2000 Feb; 66(14):PL175-81. PubMed ID: 10755474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
    Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
    Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
    He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism].
    Lou YQ; Kuang TY
    Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):23-8. PubMed ID: 7604218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.